Myasthenia Gravis Reflexive Panel
Also known as: MG R PAN
Use
The Myasthenia Gravis Reflexive Panel assists in establishing or confirming a clinical diagnosis of myasthenia gravis by testing for antibodies associated with this condition. Approximately 85-90% of patients with myasthenia gravis express antibodies to the acetylcholine receptor (AChR), including binding, blocking, and modulating antibodies. These antibodies can impair neuromuscular transmission, leading to muscle weakness. The panel utilizes a reflexive approach where initial findings may prompt additional antibody testing, ensuring a comprehensive assessment.
Special Instructions
Not provided.
Limitations
The test has a limitation in that approximately 10-15% of individuals with confirmed myasthenia gravis may not express measurable binding, blocking, or modulating antibodies. Negative test results do not rule out the diagnosis of myasthenia gravis, as some patients may have antibodies that are not detected by the available assays. Clinical correlation is required to interpret test results accurately.
New York Approved
Methodology
Immunoassay (RIA)
Biomarkers
LOINC Codes
- 11034-6 - AChR Bind Ab Ser-sCnc
- 42937-3 - AChR Block Ab/AChR Total SFr Ser
Result Turnaround Time
3-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated. Avoid repeated freeze/thaw cycles.
Causes for Rejection
Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |
Other tests from different labs that may be relevant